New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 22, 2014
08:44 EDTACT, FRXActavis shares should be bought ahead of guidance, says Sterne Agee
After reevaluating its assumptions regarding the synergies that Actavis (ACT) can generate from its acquisition of Forest Labs (FRX), Sterne Agee raised its price target on Actavis to $250 from $230. The firm recommends buying Actavis ahead of guidance for the combined company ,which the firm expects to be provided in July. Sterne Agee keeps a Buy rating on Actavis.
News For ACT;FRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ACT;FRX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use